Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function

摘要

The present invention relates to the use of 2,5-dihydroxybenzenesulfonic compounds for the manufacture of medicament for the regulation of nitric oxide (NO) synthesis and/or the regulation of EDHF (Endothelium-derived-Hyperpolarizing-Factor) in the endothelium of humans or animals, whereby the medicament is administered in a daily dose of the 2,5-dihydroxybenzenesulfonic compounds of formula I of <500 mg.